Synonyms: AQX-1125 | AQX1125
Compound class:
Synthetic organic
Comment: Rosiptor (AQX-1125) is an investigational allosteric activator of the SH2 domain-containing inositol 5'-phosphatase 1, SHIP1 (HGNC gene symbol INPP5D) [3]. SHIP1 is a negative regulatory phosphatase in the PI3K pathway, a signalling pathway that plays a central role in cellular activation, proliferation, and survival, and which is strongly implicated in inflammatory disorders and cancer. Agonists that activate SHIP1 are being actively developed (as alternatives to direct PI3K inhibitors) for their potential anti-inflammatory action. AQX-1125 is claimed in patent WO2014158654, where it appears to be referred to as compound 9 (without the acetate) [1].
|
|
Immunopharmacology Comments |
Rosiptor is a first-in-class clinical-stage SHIP1 activating small molecule drug. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Atopic dermatitis |
Disease Ontology:
DOID:3310 OMIM: 603165 |
Phase 2 clinical trial NCT02324972 completed. | |
Interstitial cystitis |
Disease Ontology:
DOID:13949 |
Phase 3 study for interstitial cystitis/bladder pain syndrome is ongoing (see NCT02858453). | |
Chronic obstructive pulmonary disease |
Disease Ontology:
DOID:3083 |
Phase 3 clinical candidate for COPD. |